INCSHR 1210Alternative Names: INCSHR1210; SHR1210
Latest Information Update: 15 Dec 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Incyte Corporation; Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action PDCD 1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatocellular carcinoma
- Phase I/II Solid tumours
- Phase I Breast cancer; Malignant melanoma
Most Recent Events
- 07 Nov 2016 Incyte completes enrolment in its phase I trial for Solid tumours (Late-stage disease, Second line therapy or greater) in Australia (NCT02492789)
- 01 Nov 2016 Phase-II/III clinical trials in Hepatocellular carcinoma (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT02989922)
- 18 Apr 2016 Jiangsu HengRui Medicine plans a phase I trial for Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in China (IV) (NCT02742935)